A Systematic Review and Meta-Analysis: Efficacy and Toxicity Profile of Ixazomib for Treatment of Multiple Myeloma

Conclusion:In our pooled analysis (95%CI), Ixazomib has shown promising efficacy both in NDMM as well as RRMM. Especially in three drug regimen it showed an estimated ORR of 84.8% in NDMM and 56.3% RRMM.Cytopenia was a common side effect.Peripheral neuropathy was noted to be a rare side-effect (2.6%) in RRMM. Further studies are required to evaluate efficacy and safety of ixazomib in combination therapies in NDMM.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Shafqat, M., Jamil, F., Shah, Z., Khan, A. Y., Durer, S., Durer, C., Aslam, S., Selene, I. I., Qureshi, A., Abu Zar, M., Hassan, S. S., Jose, J. A., Faridi, W., Anwer, F. Tags: 653. Myeloma: Therapy, excluding Transplantation Source Type: research